Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Aristotle International Equity Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"Aristotle International underperformed in Q2, swapping Novartis for Roche in pharmaceuticals while Cameco led on nuclear energy tailwinds. Consulting headwinds hurt Accenture despite strong AI bookings."
The Aristotle International Equity Fund returned -0.95% in Q2 2024, underperforming the MSCI EAFE Index (-0.42%). The fund made a significant portfolio change, selling Novartis after over a decade to purchase Roche, viewing it as a more optimal investment in personalized healthcare. Key contributors included Cameco, benefiting from increased government support for nuclear energy and 25% production growth, and DBS Group, which reported strong results with expanding margins. Detractors included Accenture, facing consulting industry headwinds from reduced corporate spending amid higher rates, and Magna International, which lowered guidance due to EV adoption slowdown. The fund maintains its focus on individual business fundamentals rather than macro predictions, seeking high-quality companies with competitive advantages. Geopolitical tensions and interest rate uncertainty present ongoing risks, while selective central bank easing and nuclear energy support provide potential catalysts. The portfolio emphasizes long-term value creation through careful security selection.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
The fund demonstrates moderate-high conviction through specific position changes (selling decade-long Novartis holding for Roche), detailed thesis explanations for individual holdings, and clear catalyst identification. However, the diversified portfolio structure and measured language prevent a higher score.
Growth Outlook
The fund expresses cautious optimism, acknowledging mixed global equity markets and economic resilience with 3.2% global growth, but also noting macroeconomic uncertainty and geopolitical tensions. The tone is balanced with selective positive views on specific opportunities.
Risk Appetite
The fund demonstrates selective risk appetite through active portfolio changes (Novartis to Roche swap) but maintains a measured approach. No indication of aggressive positioning or significant exposure changes, suggesting moderate risk tolerance.
Capital Deployment
The fund engaged in capital rotation by selling Novartis to fund Roche purchase, but this represents reallocation rather than net deployment. No evidence of cash level changes or net new capital being put to work.
Forward Guidance
The fund explicitly states they will continue focusing on individual businesses rather than attempting macro predictions, indicating a steady-state approach with no clear directional bias for increased or decreased deployment.
Language Signal
Language is balanced with selective optimism around specific holdings (Roche catalysts, Cameco opportunities) offset by acknowledgment of headwinds (consulting industry softening, geopolitical tensions). Slightly more constructive than bearish overall.
Perceived Risk
The fund acknowledges moderate risks including macroeconomic uncertainty, higher interest rates affecting corporate spending, and ongoing geopolitical tensions. Risk discussion is present but not central to the letter, representing standard risk awareness.
Opportunity Density
The fund demonstrates selective opportunity identification, making targeted changes (Roche purchase) and highlighting specific catalysts across holdings. The approach suggests reasonable opportunity availability but requires selectivity rather than abundant choices.
Time Horizon
The fund explicitly mentions three- to five-year investment horizons for catalysts, demonstrates patience through decade-long holdings (Novartis), and emphasizes long-term business fundamentals over short-term macro factors. This indicates a genuinely long-term approach.
